Journal of Substance Abuse Treatment
Volume 14, Issue 6 , Pages 529-534, November 1997

Naltrexone pharmacotherapy for opioid dependent federal probationers☆

  • James W. Cornish, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to James W. Cornish, MD, Treatment Research Center, 3900 Chestnut Street, Philadelphia, PA 19104-6178.
    • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    • ,
  • David Metzger, PhD

      Affiliations

    • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    • ,
  • George E. Woody, MD

      Affiliations

    • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    • ,
  • David Wilson, MEd

      Affiliations

    • United State Probation Office, Eastern District of Pennsylvania, Philadelphia, PA 19106 USA
    • ,
  • A.Thomas McLellan, PhD

      Affiliations

    • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    • ,
  • Barry Vandergrift

      Affiliations

    • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    • ,
  • Charles P. O'Brien, MD, PhD

      Affiliations

    • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Department of Veterans Affairs Medical Center, Philadelphia, PA 19104, USA

Received 26 July 1996; received in revised form 7 March 1997; accepted 31 March 1997.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Work supported by NIDA Grant DA05186. Thanks to the Federal Judges, U.S. Probation Officers and management staff of the Eastern District of Pennsylvania for their tremendous support and invaluable assistance. Narcan® brand naloxone, ReVia® brand naltrexone, and patient brochures describing ReVia® were generously supplied by DuPont Pharmaceuticals. Thanks also to Assunta Cuccia, Phase Four Manager, DuPont Pharmaceuticals for continuous professional support.

PII: S0740-5472(97)00020-2

Journal of Substance Abuse Treatment
Volume 14, Issue 6 , Pages 529-534, November 1997

Article Tools